AU2001271037A1 - Pharmaceutical compositions containing dds compounds - Google Patents

Pharmaceutical compositions containing dds compounds

Info

Publication number
AU2001271037A1
AU2001271037A1 AU2001271037A AU7103701A AU2001271037A1 AU 2001271037 A1 AU2001271037 A1 AU 2001271037A1 AU 2001271037 A AU2001271037 A AU 2001271037A AU 7103701 A AU7103701 A AU 7103701A AU 2001271037 A1 AU2001271037 A1 AU 2001271037A1
Authority
AU
Australia
Prior art keywords
pharmaceutical compositions
compositions containing
dds compounds
containing dds
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001271037A
Inventor
Shuichi Sugie
Masayuki Takahashi
Masahito Takeuchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Pharmaceutical Co Ltd
Original Assignee
Daiichi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Pharmaceutical Co Ltd filed Critical Daiichi Pharmaceutical Co Ltd
Publication of AU2001271037A1 publication Critical patent/AU2001271037A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
AU2001271037A 2000-07-13 2001-07-11 Pharmaceutical compositions containing dds compounds Abandoned AU2001271037A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000213083 2000-07-13
JP2000-213083 2000-07-13
PCT/JP2001/006020 WO2002005855A1 (en) 2000-07-13 2001-07-11 Pharmaceutical compositions containing dds compounds

Publications (1)

Publication Number Publication Date
AU2001271037A1 true AU2001271037A1 (en) 2002-01-30

Family

ID=18708899

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001271037A Abandoned AU2001271037A1 (en) 2000-07-13 2001-07-11 Pharmaceutical compositions containing dds compounds

Country Status (12)

Country Link
US (1) US6815435B2 (en)
EP (1) EP1308171A1 (en)
KR (1) KR20030023697A (en)
CN (1) CN1556712A (en)
AR (1) AR031714A1 (en)
AU (1) AU2001271037A1 (en)
BR (1) BR0112417A (en)
CA (1) CA2415922A1 (en)
MX (1) MXPA03000387A (en)
NO (1) NO20030139L (en)
RU (1) RU2003100532A (en)
WO (1) WO2002005855A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166513A1 (en) * 2000-06-29 2003-09-04 Akihiro Imura Dds compound and process for the preparation thereof
TWI320713B (en) 2001-06-01 2010-02-21 Neochemir Inc
TW200306314A (en) * 2002-04-16 2003-11-16 Tanabe Seiyaku Co Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation
KR20090091365A (en) * 2002-12-10 2009-08-27 네오케미아 가부시키가이샤 Skin material for external use, and antipruritic agent for external use and wrinkle-reducing instrument using the same
TW200727900A (en) * 2005-07-27 2007-08-01 Yakult Honsha Kk Aqueous solution preparation containing camptothecins
JO3112B1 (en) 2010-03-29 2017-09-20 Ferring Bv A fast dissolving pharmaceutical composition
AU2013263795B2 (en) * 2010-03-29 2015-09-17 Ferring B.V. A fast dissolving pharmaceutical composition
CN102834091B (en) 2010-03-29 2015-04-22 辉凌公司 A fast dissolving pharmaceutical composition
NZ620897A (en) 2011-09-16 2016-07-29 Ferring Bv A fast dissolving pharmaceutical composition
KR102417310B1 (en) 2012-10-11 2022-07-05 다이이찌 산쿄 가부시키가이샤 Method for producing a glycinamide compound
US9872924B2 (en) 2012-10-19 2018-01-23 Daiichi Sankyo Company, Limited Antibody-drug conjugate produced by binding through linker having hydrophilic structure
KR102088169B1 (en) 2013-12-25 2020-03-12 다이이찌 산쿄 가부시키가이샤 Anti-trop2 antibody-drug conjugate
CN110464847B (en) 2014-01-31 2024-02-09 第一三共株式会社 anti-HER 2 antibody-drug conjugates
KR102445502B1 (en) 2014-04-10 2022-09-21 다이이찌 산쿄 가부시키가이샤 Anti-her3 antibody-drug conjugate
EP3130608B1 (en) 2014-04-10 2019-09-04 Daiichi Sankyo Co., Ltd. (anti-her2 antibody)-drug conjugate
AU2015369185B2 (en) 2014-12-26 2020-10-22 Nippon Kayaku Kabushiki Kaisha Pharmaceutical preparation of camptothecin-containing polymer derivative
BR112017027690A2 (en) 2015-06-29 2018-10-09 Daiichi Sankyo Co Ltd “method for producing an antibody-drug conjugate composition, and antibody-drug conjugate composition
CA2995053A1 (en) 2015-09-03 2017-03-09 Nippon Kayaku Kabushiki Kaisha Pharmaceutical composition containing camptothecin polymer derivative
CA3015459A1 (en) 2016-03-01 2017-09-08 Nippon Kayaku Kabushiki Kaisha Pharmaceutical preparation containing camptothecin-based polymeric derivative
CA3046293A1 (en) 2016-12-12 2018-06-21 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and immune checkpoint inhibitor
TWI780104B (en) 2017-01-17 2022-10-11 日商第一三共股份有限公司 Anti gpr20 antibodies and anti gpr20 antibody-drug conjugates, as well as manufacturing method and use thereof
TWI794230B (en) 2017-05-15 2023-03-01 日商第一三共股份有限公司 Anti cdh6 antibodies and anti cdh6 antibody drug conjugates, as well as manufacturing method thereof
EP3677568A4 (en) 2017-08-31 2021-05-12 Daiichi Sankyo Company, Limited Novel method for producing antibody-drug conjugate
WO2019044947A1 (en) 2017-08-31 2019-03-07 第一三共株式会社 Improved method for producing antibody-drug conjugate
HRP20230787T1 (en) 2018-05-18 2023-10-27 Glycotope Gmbh Anti-muc1 antibody
US11634508B2 (en) 2019-07-10 2023-04-25 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics
EP3996749A1 (en) 2019-07-10 2022-05-18 Cybrexa 3, Inc. Peptide conjugates of microtubule-targeting agents as therapeutics

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5711909A (en) * 1980-06-23 1982-01-21 Shionogi & Co Ltd Stable freeze-dried preparation of beta-lactam
JPS61165322A (en) * 1985-01-14 1986-07-26 Microbial Chem Res Found Spergualin composition for pharmaceutical use
CN1195990A (en) 1995-09-13 1998-10-14 日本新药株式会社 PGE1-containing freeze-dried preparation and process for production thereof
NZ331372A (en) * 1996-02-19 2000-01-28 Nycomed Imaging As freeze-dried vesicle containing a thermally stabilized ultrasound contrast agent
AU2034097A (en) * 1996-03-19 1997-10-10 Morgan Crucible Company Plc, The A conduit
JPH10212241A (en) 1996-05-27 1998-08-11 Sumitomo Pharmaceut Co Ltd Preparation stably containing bdnf
TW527183B (en) 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
WO2000018401A1 (en) 1998-09-29 2000-04-06 Takeda Chemical Industries, Ltd. Antimycotic drug composition

Also Published As

Publication number Publication date
US20030148931A1 (en) 2003-08-07
RU2003100532A (en) 2004-07-20
US6815435B2 (en) 2004-11-09
CA2415922A1 (en) 2002-01-24
MXPA03000387A (en) 2003-09-22
KR20030023697A (en) 2003-03-19
WO2002005855A1 (en) 2002-01-24
NO20030139D0 (en) 2003-01-10
EP1308171A1 (en) 2003-05-07
BR0112417A (en) 2003-07-01
NO20030139L (en) 2003-03-13
CN1556712A (en) 2004-12-22
AR031714A1 (en) 2003-10-01

Similar Documents

Publication Publication Date Title
AU2001271037A1 (en) Pharmaceutical compositions containing dds compounds
AU781269C (en) Pharmaceutical compositions
AU2001250420A1 (en) Pharmaceutical compositions
AU2002222118A1 (en) Pharmaceutical compositions for inhalation
AU2001274307A1 (en) Pharmaceutical compositions
AU1071301A (en) Pharmaceutical compounds
AU2002363361A1 (en) Pharmaceutical compositions containing oxybutynin
IL148864A0 (en) Pharmaceutical compositions containing nimesulide
AU2002217464A1 (en) Medicinal compositions containing aspirin
AU2002302147A1 (en) Pharmaceutical composition
AU3556400A (en) Pharmaceutical compositions
AU1574900A (en) Pharmaceutical compositions containing insulin
AU2001262733A1 (en) Medicinal compositions containing propenone derivatives
AU2002214324A1 (en) Medicinal compositions
AU2002221115A1 (en) Medicinal compositions having improved absorbability
HUP0000137A3 (en) Controller-release pharmaceutical composition containing anangetics
AU6370299A (en) Pharmaceutical compositions containing tetrahydroisoquinoline compounds
AU4304400A (en) Novel pharmaceutical compositions comprising 2-isoxazole-8-aminotetralin derivatives
AU2001273919A1 (en) Pharmaceutical compositions
AU6460400A (en) Pharmaceutical compositions
AU7937500A (en) Pharmaceutical composition containing midazolam
AU2002215114A1 (en) Pharmaceutical compositions for inhalation
AU6460200A (en) Pharmaceutical compositions
AU5722900A (en) Pharmaceutical compounds
AU4085201A (en) Pharmaceutical composition